Address
Sector 14, Road no. 18, Uttara, 1230
Dhaka, Bangladesh
Rx Prescripttion Only-YMYL Medical Content
Palboxen 125 mg
Palbociclib 125mg capsules – Everest Pharmaceuticals Ltd.
Indicated for adults with HR-positive, HER2-negative advanced or metastatic breast cancer — in combination with an aromatase inhibitor as initial endocrine-based therapy, or with fulvestrant in patients with disease progression following endocrine therapy. Also approved for use in men with advanced breast cancer with appropriate gonadal suppression.
- Clinical outcomes at a glance
27.6 mo
Median PFS with palbociclib + letrozole as first-line therapy vs 14.5 months with letrozole alone (PALOMA-2)
11.2 mo
Median PFS with palbociclib + fulvestrant after prior endocrine therapy vs 4.6 months with fulvestrant alone (PALOMA-3)
1st
First-in-class CDK4/6 inhibitor — established this entire drug category for HR-positive breast cancer
21/7
21 days on, 7 days off — built-in recovery window allowing bone marrow cells to recover from reversible, cytostatic neutropenia
- Am I a candidate? — Take Decesion
1
Confirm HR-positive, HER2-negative status and treatment line
Requires confirmed hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. Used with an aromatase inhibitor as first-line therapy, or with fulvestrant if disease has progressed on prior endocrine therapy.
2
Baseline complete blood count — neutropenia monitoring from the start
Neutropenia is the most common adverse event — baseline CBC is required, with repeat monitoring before each cycle and on day 14 of the first two cycles. Confirm these appointments are scheduled before your first dose.
3
Review for strong CYP3A inhibitors and inducers — and grapefruit
Strong CYP3A inhibitors (including certain antifungals, clarithromycin, ritonavir) can increase palbociclib exposure by up to 87%; strong inducers (rifampin, phenytoin, carbamazepine, enzalutamide, St. John’s Wort) can reduce it by up to 85%. Grapefruit should be avoided throughout treatment.
4
Confirm the dose-reduction plan in advance
If significant neutropenia or other grade 3/4 toxicity occurs, the first dose reduction is to 100mg (Palboxen 100mg or Palbonix 100mg), followed if needed by 75mg. If further reduction below 75mg is required, treatment should be discontinued — confirm this hierarchy with your oncologist before starting.
Important safety information: Neutropenia is the most frequently reported adverse reaction — monitor CBC before starting, before each cycle, and on day 14 of the first two cycles. Febrile neutropenia and fatal neutropenic sepsis have occurred. Pulmonary embolism and venous thromboembolic events have been reported. Embryo-fetal toxicity — effective contraception required during treatment and for 3 weeks after the final dose. Do not breastfeed during treatment or for 3 weeks after the final dose.
- common side effects to know
- Neutropenia (most common, ~80%)
- Fatigue / nausea
- Hair thinning / mouth sores
- Numbness/tingling of arms or legs
- Febrile neutropenia / serious infection
- Pulmonary embolism / blood clots
- Trust & expertise
- FDA Approved 2015, Expanded 2016
- EMA Approved 2016
- NCCN Breast Cancer Guidelines (Category 1)
- PALOMA-1 / PALOMA-2 / PALOMA-3 Trials
MD
Medical Oncologist Review
Board-certified oncologist · 12+ years in thoracic malignancies
“Palbociclib was the first CDK4/6 inhibitor to reach patients and the PALOMA-2 and PALOMA-3 PFS results were transformative for HR-positive metastatic breast cancer — nearly doubling progression-free survival in the first-line setting. The neutropenia is very common but typically manageable and reversible, which is exactly why the regular CBC monitoring schedule matters most in the first two cycles. The CYP3A interaction profile is broad enough that a formal medication review before starting is not optional — interactions with commonly used antifungals and certain antibiotics can meaningfully affect drug exposure.”
Content reviewed against FDA prescribing information, NCCN Guidelines v2.2024, and published Phase III trial data. Last updated June 2026.
Ready to discuss Tagrisso with your care team?
These steps help you have an informed conversation. A confirmed EGFR mutation result is the starting point for any treatment decision.
Questions to ask my healthcare provider
We covered this in full detail earlier in our conversation for the Palbonix 125mg page — here’s the complete set pulled forward rather than repeating the research.
Before confirming palbociclib as your treatment
- Has my HR-positive, HER2-negative status been confirmed?
- Am I starting first-line treatment with an aromatase inhibitor, or is this being added after progression on prior endocrine therapy with fulvestrant?
- What endocrine therapy have I already tried, if any, and how did my cancer respond?
- Are there clinical trials I should know about?
About neutropenia and blood count monitoring
- Can you walk me through the exact CBC monitoring schedule — before starting, before each cycle, and on day 14 of the first two cycles?
- What blood count thresholds would trigger a dose interruption, reduction, or delay?
- What symptoms of infection — fever, chills, unusual fatigue — should prompt me to call immediately?
- I understand this neutropenia tends to be reversible and different from chemotherapy-related neutropenia — can you explain what that means in practical terms?
About blood clot risk
- Do I have any personal or family history of blood clots that’s relevant here?
- What symptoms of pulmonary embolism or deep vein thrombosis should prompt emergency care?
About the CYP3A drug interaction profile — particularly important for this drug
- Can we review every medication, supplement, and over-the-counter product I currently take for CYP3A inhibitors or inducers?
- Strong CYP3A inhibitors including certain antifungals (itraconazole, voriconazole, ketoconazole) and clarithromycin can increase palbociclib exposure by up to 87% — am I on anything in this category?
- Strong CYP3A inducers including rifampin, phenytoin, carbamazepine, enzalutamide, and St. John’s Wort can reduce exposure by up to 85% — am I on anything here?
- Should I avoid grapefruit and grapefruit juice throughout treatment?
- If I’m prescribed something new by another doctor, what should they know?
About the dose-reduction plan — know this before starting
- If significant neutropenia or other grade 3/4 toxicity occurs, what is the dose-reduction sequence — 125mg → 100mg → 75mg → stop?
- What specific findings would trigger each step?
- If a dose is reduced, is there ever a path back to the higher dose?
About the dosing schedule
- Can you confirm the 21-days-on, 7-days-off cycle clearly?
- Must it be taken with food, and does the size of the meal matter?
- What should I do if I miss a dose or vomit after taking it?
- Can the capsules be opened or dissolved?
About the combination partner medication
- If taking with an aromatase inhibitor: how does that schedule work alongside palbociclib?
- If taking with fulvestrant: can you explain the injection schedule and visit frequency?
About managing common side effects
- Hair thinning rather than full hair loss is typical — what can help?
- What can help with fatigue, nausea, or mouth sores if they occur?
About contraception
- What contraception is required during treatment and for 3 weeks after the final dose?
- Does this also apply to male partners?
About monitoring response
- What imaging schedule will track whether this is working?
- How soon might we expect to see signs of response?
About the longer road
- If palbociclib stops working or isn’t tolerated, what would be considered next?
- Are there patient assistance programs through Pfizer if cost is a concern?
A practical tip: Because strong CYP3A inhibitors can increase palbociclib exposure by nearly 90% and strong inducers can reduce it by 85%, ask your oncologist and pharmacist to conduct a formal medication review before starting — including not just prescription drugs but supplements and herbal products, since St. John’s Wort is a strong CYP3A inducer that patients sometimes take without considering drug interactions.
compare with other therapies
We’ve covered this three-way comparison twice already in this conversation — here are the key findings pulled forward concisely.
All three share the same core mechanism but differ in selectivity, dosing, and OS data
| Palbociclib (Ibrance) | Ribociclib (Kisqali) | Abemaciclib (Verzenio) | |
|---|---|---|---|
| FDA approval | 2015 — first CDK4/6 inhibitor | 2017 | 2017 |
| Dosing | 125mg once daily, 21/7 cycle | 600mg once daily, 21/7 cycle | 150mg twice daily, continuous |
| Cardiac monitoring | Not required | Yes — QT monitoring needed | Not required |
Overall survival — the most clinically significant differentiator
Palbociclib’s PALOMA-2 final OS analysis showed numerically longer survival versus placebo but the difference was not statistically significant. Ribociclib and abemaciclib have both demonstrated statistically significant overall survival benefits across multiple trials. This is the single most important clinical distinction among the three and has shifted prescribing patterns in guidelines over time.
Side effects — genuinely different patterns
Palbociclib: neutropenia (~80%) dominates; lower GI burden
Ribociclib: neutropenia plus unique QT prolongation risk requiring baseline and periodic ECG — no equivalent requirement for the other two
Abemaciclib: diarrhea is the defining, often early side effect; meaningfully less neutropenia than the other two; liver enzyme monitoring needed
Dosing schedule
Abemaciclib’s continuous twice-daily dosing without a scheduled off-week is structurally distinct — some patients prefer no break in the regimen rhythm, others find the absence of a recovery week harder.
Monotherapy activity
Abemaciclib has demonstrated activity as a single agent in heavily pretreated patients — a use case less established for palbociclib or ribociclib.
Where clinical preference tends to land
Palbociclib: longest track record, broad real-world experience, avoids QT cardiac monitoring
Ribociclib: confirmed OS benefit, suitable for patients without significant cardiac risk
Abemaciclib: confirmed OS benefit, preferred where neutropenia is a greater concern than diarrhea, monotherapy option available
Bottom line
All three produce broadly comparable progression-free survival. Ribociclib and abemaciclib have confirmed overall survival benefit where palbociclib’s OS result was not statistically significant — the most clinically meaningful difference. Ribociclib requires QT cardiac monitoring; abemaciclib’s dominant challenge is diarrhea rather than neutropenia. The choice should reflect your specific OS data preferences, cardiac risk profile, side-effect tolerance, and dosing preferences — all worth a direct, individualized conversation with your oncologist.
How does testing work
We’ve covered this mechanism in full detail twice already in this conversation — here are the key points pulled forward concisely.
The cell cycle checkpoint that matters
Every dividing cell must pass through G1 → S phase — the point of no return where it commits to copying its DNA. This transition is the critical checkpoint CDK4/6 inhibitors target.
The molecular players — cyclin D, CDK4/6, and RB
Cyclin D1, produced in response to estrogen signaling in HR-positive breast cancer, pairs with CDK4 or CDK6 to form an active complex. This complex phosphorylates the retinoblastoma protein (RB) — normally a “brake” holding the cell in G1. Phosphorylation releases this brake, allowing the cell to enter S phase and divide.
Why HR-positive breast cancer specifically depends on this pathway
Estrogen drives cyclin D1 production directly — meaning these cancer cells are particularly dependent on CDK4/6 to push past the G1/S checkpoint. Palbociclib reduced cellular proliferation of estrogen receptor-positive breast cancer cell lines by blocking progression from G1 into S phase. This is precisely why CDK4/6 inhibitors work so specifically well in HR-positive disease.
How palbociclib blocks this
Palbociclib binds and inhibits CDK4 and CDK6 directly, preventing RB phosphorylation. With the brake remaining on, the cell stays locked in G1 regardless of how much estrogen-driven growth signal is pushing it — unable to commit to DNA replication or division.
Why combining with endocrine therapy is so synergistic
Endocrine therapy (aromatase inhibitors or fulvestrant) works upstream — reducing estrogen’s ability to drive cyclin D1 production. Palbociclib works downstream — directly blocking CDK4/6 regardless of how much cyclin D1 is present. Attacking the same pathway at two different points produces more complete blockade than either drug alone — explaining the dramatic PALOMA PFS improvements.
Why the neutropenia is reversible — the cytostatic vs cytotoxic distinction
The neutropenia associated with CDK4/6 inhibitors is rapidly reversible, reflecting a cytostatic rather than cytotoxic mechanism. Palbociclib temporarily arrests bone marrow precursor cells in G1 rather than killing them — they resume dividing during the 7-day off-week. This is why dose reduction to 100mg for neutropenia management is a legitimate clinical option that maintains treatment continuity, and why the neutropenia pattern differs fundamentally from chemotherapy-induced bone marrow suppression.
The bigger picture
Palbociclib exploits HR-positive breast cancer’s specific CDK4/6 dependency — precisely jamming the cell cycle checkpoint these estrogen-driven cancer cells rely on, while producing reversible rather than destructive effects on normal tissues. Combined with endocrine therapy attacking the same pathway upstream, this dual approach is what drove the landmark PALOMA PFS improvements and established CDK4/6 inhibition as a foundational pillar of modern HR-positive metastatic breast cancer treatment.
Medical disclaimer: This page is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Osimertinib is a prescription medication that must only be used under the supervision of a qualified oncologist. Clinical outcomes data is drawn from published Phase III trials; individual results vary. Always consult your healthcare provider and refer to the full prescribing information before making any treatment decisions. Emergency: call your local emergency services or poison control immediately if you experience serious adverse effects.
